Ramez Eskander, MD, and Krishnansu Tewari, MD, discuss the evolving treatment landscape in the management of advanced or recurrent endometrial cancer.
EP. 1: Overview of Endometrial Carcinoma
Ramez Eskander, MD, and Krishnansu Tewari, MD, provide an overview of endometrial cancer, including prevalence, staging criteria, and molecular profiling.
EP. 2: Patient Profile Presentation: A 64-Year-Old Woman With Recurrent Endometrial Cancer
Ramez Eskander, MD, presents the profile of a 64-year-old postmenopausal woman diagnosed with recurrent endometrial carcinoma for discussion.
EP. 3: Recent Data on IO-Based Combination Regimens for First-line Treatment of Advanced Endometrial Carcinoma
Krishnansu Tewari, MD, reviews emerging data from two studies investigating immunotherapy-based combination regimens for the first-line treatment of advanced endometrial cancer.
EP. 4: Available Frontline Treatment Options for Patients With Advanced or Recurrent Endometrial Cancer
Krishnansu Tewari, MD, details the first-line treatment options for patients with recurrent endometrial cancer.
EP. 5: Approaches to Treatment Sequencing for Patients With Advanced Endometrial Cancer
Experts explain how they change their treatment strategies if a patient with advanced endometrial cancer does not respond to treatment or experiences disease progression.
EP. 6: Patient Profile Presentation: A 68-Year-Old Woman With Recurrent Endometrial Cancer
Krishnansu Tewari, MD, presents the profile of a 68-year-old postmenopausal woman with recurrent endometrial cancer for discussion.
EP. 7: Emerging Targeted Treatment Options for Patients With Advanced Endometrial Cancer
Key opinion leaders discuss targeted treatment regimens for advanced or recurrent endometrial cancer that are currently under development.
EP. 8: The Future of Clinical Care for Patients With Advanced Endometrial Cancer
Closing their conversation, Ramez Eskander, MD, and Krishnansu Tewari, MD, share how they envision the future treatment landscape for patients with advanced endometrial cancer.
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC